AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

Immunovant Inc. (IMVT)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

20.73

-0.09 (-0.43%)

At close: Feb 20, 2025, 3:59 PM

20.45

-1.37%

After-hours: Feb 20, 2025, 04:00 PM EST

undefined% (undefined)

Bid	20.1
Market Cap	3.52B
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	-2.62
PE Ratio (ttm)	-7.91
Forward PE	n/a
Analyst	Buy

Ask	21.85
Volume	611,671
Avg. Volume (20D)	1,129,238
Open	20.86
Previous Close	20.82
Day's Range	20.68 - 21.30
52-Week Range	19.07 - 39.55
Beta	undefined

About IMVT

Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of myasthenia gravis and thyroid eye disease, as well as completed initiation of Phase II clinical trials for...

[Show more]

Industry Biotechnology

Sector Healthcare

IPO Date Jun 21, 2019

Employees 207

Stock Exchange NASDAQ

Ticker Symbol IMVT

Website https://immunovant.com

Full Company Profile

Analyst Forecast

According to 12 analyst ratings, the average rating for IMVT stock is "Buy." The 12-month stock price forecast is $46, which is an increase of 121.85% from the latest price.

Buy 91.67%

Hold 8.33%

Sell 0.00%

Stock Forecasts

Why Price Moved

2 weeks ago

-9.55%

Immunovant shares are trading lower. The company r... Unlock content with Pro Subscription

3 months ago

-4.74%

Immunovant shares are trading lower after the company reported worse-than-expected Q2 EPS results.

News

1 week ago · zacks.com

Immunovant (IMVT) Loses -15.47% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

Immunovant (IMVT) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revisin...

2 weeks ago · zacks.com

IMVT Q3 Loss Wider Than Expected, Stock Down, Pipeline in Focus

Immunovant stock down on dismal third-quarter fiscal 2025 results. It is on track to initiate 10 studies on IMVT-1402 across various autoimmune indications.

1 month ago · 247wallst.com

A Huge Biotech Purchase Highlights New Year's Insider Buying

The year started off slow as far as insider purchases go.

1 month ago · seekingalpha.com

Immunovant: Continued FcRn Targeting With IMVT-1402 Pivotal Study

Immunovant aims to initiate a pivotal registration study for IMVT-1402 targeting Graves' Disease by the end of 2024, with 4–5 trials in other IgG-mediated autoimmune disorders by March 2025. IMVT-1402...